Harmon Cyrus sold $291K of OLMA
Harmon Cyrus sold 25,000 shares of Olema Pharmaceuticals, Inc. (OLMA) at an average of $11.65 ($11.58–$11.71, $0.29M total) across 2 trades over 2026-07-23 to 2026-07-24.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale provides a datapoint on insider behavior, but it does not introduce new operational, clinical, or financial information for OLMA.
Market read
Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a sustained repricing without accompanying company catalysts.
What to watch
The article does not state total insider holdings pre-sale beyond shares after transaction, nor does it provide context on compensation, tax liabilities, or whether other insiders sold/bought around the same time.
Background
This is an SEC Form 4 insider transaction for Olema Pharmaceuticals, Inc., reported by a director.
Ticker impact
Olema Pharmaceuticals director Harmon Cyrus sold 25,000 shares in open-market transactions totaling $291,162.50 at $11.5790–$11.7140.
Likely limited, short-lived sentiment impact; no clear directional signal from this single sale.
The filing is a Form 4 insider transaction with specified sale price range and total value, but it does not include new company fundamentals, guidance, or regulatory/clinical developments.
Market effects
Minimal read-across to biotech sector; this is company-specific insider liquidity/sentiment rather than sector-wide news.
None.
None.
Counterpoint
Director sales can be planned for diversification or tax needs; the absence of a stated 10b5-1 plan does not necessarily imply negative information.
Key entities
- issuerOlema Pharmaceuticals, Inc.
Company whose director reported an open-market sale of shares via SEC Form 4.
- insiderHarmon Cyrus
Director who sold 25,000 shares for about $291,162.50 at $11.5790–$11.7140.